Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of MF/OXY in the treatment of adenoid hypertrophy children with severe allergic rhinitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangzhou Women and Children's Medical Center
• Treatments: Mometasone Furoate; Oxymetazoline; Phenylephrine

Criteria

Inclusion Criteria:

• adenoid occluding at least 75% of the nasopharynx at nasal endoscopy

• age between 5 and 11 years

• chronic obstructive nasal symptoms no less than 12 months

• moderate-to-severe AR

Exclusion Criteria:

• tonsillar hypertrophy

• upper respiratory infection within the last 2 weeks

• sinonasal anatomic anomalies or diseases

• craniofacial malformations

• genetic diseases (i.e., Down's syndrome)

• neurologic or cardiovascular diseases

• immunodeficiency

• history of epistaxis

• asthma

• hypersensitivity to MF or OXY

• undergoing intranasal, topical, or systemic steroid or antibiotic treatment within the past 4 weeks